A phase II dose-ranging study of mirabegron in patients with overactive bladder

Christopher R. Chapple, Vladimir Dvorak, Pjotr Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte Bosman, Peter Boerrigter, Ted Drogendijk, Arwin Ridder, Ingrid Van der Putten-Slob, Osamu Yamaguchi

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Scopus)
Original languageEnglish
Pages (from-to)1447-1458
JournalInternational Urogynecology Journal
Volume24
Issue number9
DOIs
Publication statusPublished - Sep 2013

Keywords

  • beta(3)-adrenoceptor agonist
  • Mirabegron
  • Overactive
  • Urinary bladder

Cite this

Chapple, C. R., Dvorak, V., Radziszewski, P., Van Kerrebroeck, P., Wyndaele, J. J., Bosman, B., Boerrigter, P., Drogendijk, T., Ridder, A., Van der Putten-Slob, I., & Yamaguchi, O. (2013). A phase II dose-ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal, 24(9), 1447-1458. https://doi.org/10.1007/s00192-013-2042-x